text:
05127_ch_mouse_p03
05127_ch_rat_p03
NTP                                        STATISTICAL ANALYSIS OF PRIMARY TUMORS                              REPORT: PEIRPT08
LAB: Mason                                              BARIUM CHLORIDE DIHYDRATE                              DATE: 09/16/94
CONT: N01ES55115            ROUTE: DOSED WATER                                                                 NTP C#: C61074
PATHOLOGIST: A. RUSSFIELD                    S. EUSTIS                                                         CAS: 10326279
RATS(FISCHER344)
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
Bone Marrow
Clitoral Gland
Epididymis
Islets, Pancreatic
Preputial Gland
IN THE ANALYSIS OF THE STUDY OF BARIUM CHLORIDE DIHYDRATE
====================================================================================================
ORGAN                               MORPHOLOGY
-------                             ------------
Adrenal Medulla               Pheochromocytoma Benign
Pheochromocytoma: Benign, Complex, Malignant, NOS
All Organs                    Leukemia: Lymphocytic, Monocytic, Mononuclear,
or Undifferentiated
Benign Tumors
Malignant Tumors
Mammary Gland                 Fibroma, Fibroadenoma or Adenoma
Fibroma, Fibroadenoma, Carcinoma, or Adenoma
Skin                          Fibroma
Uterus                        Polyp Stromal
All Organs                    Benign Tumors
Malignant and Benign Tumors
DATE: 09/16/94                     EXPERIMENT: 05127 TEST: 01                                                 PAGE   1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- BARIUM CHLORIDE DIHYDRATE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|                       |                                                    |                                                    |
|                       |                       MALES                        |                      FEMALES                       |
|DOSE                   |   0 PPM        500 PPM      1250 PPM     2500 PPM  |   0 PPM        500 PPM      1250 PPM     2500 PPM  |
|     Adenoma                                                                                |
|TUMOR RATES            |                                                    |                                                    |
|-----------            |                                                    |                                                    |
|OVERALL (a)            |  1/59 (2%)    0/60 (0%)    0/60 (0%)    1/60 (2%)  |  1/60 (2%)    3/59 (5%)    1/59 (2%)    0/60 (0%)  |
|ADJUSTED (b)           |   4.3%         0.0%         0.0%         3.0%      |   3.2%         8.3%         2.6%         0.0%      |
|INTERIM SACRIFICE 1 (c)|  0/10 (0%)    0/10 (0%)    0/10 (0%)    0/10 (0%)  |  0/10 (0%)    0/10 (0%)    0/10 (0%)    0/10 (0%)  |
|TERMINAL (d)           |  0/22 (0%)    0/31 (0%)    0/29 (0%)    1/33 (3%)  |  1/31 (3%)    3/36 (8%)    1/38 (3%)    0/32 (0%)  |
|FIRST INCIDENCE (DAYS) |   723          ---          ---          730 (T)   |   737 (T)      737 (T)      737 (T)      ---       |
|-----------------------|                                                    |                                                    |
|STATISTICAL TESTS (f)  |                                                    |                                                    |
|LIFE TABLE             |  P=0.632      P=0.428N     P=0.447N     P=0.669N   |  P=0.168N     P=0.359      P=0.716N     P=0.494N   |
|INCIDENTAL TUMOR       |  P=0.515      P=0.628N     P=0.576N     P=0.700    |  P=0.168N     P=0.359      P=0.716N     P=0.494N   |
|LOGISTIC REGRESSION    |  P=0.603      P=0.479N     P=0.473N     P=0.727N   |  P=0.168N     P=0.359      P=0.716N     P=0.494N   |
|COCHRAN-ARMITAGE       |  P=0.577                                           |  P=0.176N                                          |
|FISHER EXACT           |               P=0.496N     P=0.496N     P=0.748N   |               P=0.303      P=0.748      P=0.500N   |
|     Pheochromocytoma Benign                                                                                |
|OVERALL (a)            | 11/59 (19%)   9/60 (15%)  11/59 (19%)   6/60 (10%) |  2/60 (3%)    4/59 (7%)    2/59 (3%)    1/60 (2%)  |
|ADJUSTED (b)           |  40.2%        27.0%        34.0%        18.2%      |   6.5%        10.3%         5.3%         2.4%      |
|INTERIM SACRIFICE 1 (c)|  0/10 (0%)    0/10 (0%)    1/10 (10%)   0/10 (0%)  |  0/10 (0%)    0/10 (0%)    0/10 (0%)    0/10 (0%)  |
|TERMINAL (d)           |  7/22 (32%)   7/31 (23%)   9/29 (31%)   6/33 (18%) |  2/31 (6%)    3/36 (8%)    2/38 (5%)    0/32 (0%)  |
|FIRST INCIDENCE (DAYS) |   691          673          452 (I)      730 (T)   |   737 (T)      647          737 (T)      669       |
|LIFE TABLE             |  P=0.046N*    P=0.180N     P=0.347N     P=0.033N*  |  P=0.233N     P=0.413      P=0.620N     P=0.474N   |
|INCIDENTAL TUMOR       |  P=0.104N     P=0.346N     P=0.493N     P=0.098N   |  P=0.229N     P=0.414      P=0.620N     P=0.456N   |
|LOGISTIC REGRESSION    |  P=0.117N     P=0.319N     P=0.538N     P=0.085N   |  P=0.227N     P=0.401      P=0.620N     P=0.473N   |
|COCHRAN-ARMITAGE       |  P=0.145N                                          |  P=0.241N                                          |
|     Pheochromocytoma Malignant                                                                                |
|FIRST INCIDENCE (DAYS) |   605          653          730 (T)      ---       |   ---          ---          ---          737 (T)   |
|LIFE TABLE             |  P=0.124N     P=0.638N     P=0.618N     P=0.200N   |  P=0.186        (e)          (e)        P=0.506    |
|INCIDENTAL TUMOR       |  P=0.130N     P=0.654N     P=0.618N     P=0.130N   |  P=0.186        (e)          (e)        P=0.506    |
|LOGISTIC REGRESSION    |  P=0.156N     P=0.684N     P=0.681N     P=0.234N   |  P=0.186        (e)          (e)        P=0.506    |
|COCHRAN-ARMITAGE       |  P=0.160N                                          |  P=0.195                                           |
|FISHER EXACT           |               P=0.684N     P=0.691N     P=0.244N   |                 (e)          (e)        P=0.500    |
|     Pheochromocytoma: Benign, Complex, Malignant, NOS                                                                           |
|OVERALL (a)            | 13/59 (22%)  11/60 (18%)  13/59 (22%)   6/60 (10%) |  2/60 (3%)    5/59 (8%)    2/59 (3%)    2/60 (3%)  |
|TERMINAL (d)           |  8/22 (36%)   8/31 (26%)  11/29 (38%)   6/33 (18%) |  2/31 (6%)    4/36 (11%)   2/38 (5%)    1/32 (3%)  |
|INCIDENTAL TUMOR       |  P=0.037N*    P=0.336N     P=0.455N     P=0.028N*  |  P=0.347N     P=0.286      P=0.620N     P=0.657N   |
|LOGISTIC REGRESSION    |  P=0.048N*    P=0.347N     P=0.531N     P=0.042N*  |  P=0.344N     P=0.277      P=0.620N     P=0.665N   |
|Brain                                                                                |
|     Oligodendroglioma, Glioma, or Astrocytoma                                                                                |
|INTERIM SACRIFICE 1 (c)|  0/10 (0%)    0/10 (0%)    0/10 (0%)    0/10 (0%)  |  0/10 (0%)    0/10 (0%)    1/10 (10%)   1/10 (10%) |
|FIRST INCIDENCE (DAYS) |   ---          ---          ---          730 (T)   |   652          ---          458 (I)      458 (I)   |
|LIFE TABLE             |  P=0.227        (e)          (e)        P=0.581    |  P=0.524N     P=0.196N     P=0.479N     P=0.479N   |
|INCIDENTAL TUMOR       |  P=0.227        (e)          (e)        P=0.581    |  P=0.506N     P=0.166N     P=0.708      P=0.426N   |
|LOGISTIC REGRESSION    |  P=0.227        (e)          (e)        P=0.581    |  P=0.554N     P=0.238N     P=0.508N     P=0.533N   |
|FISHER EXACT           |                 (e)          (e)        P=0.500    |               P=0.248N     P=0.500N     P=0.500N   |
|Clitoral/Preputial Gland                                                                                |
|FIRST INCIDENCE (DAYS) |   730 (T)      730 (T)      730 (T)      ---       |   ---          737 (T)      ---          737 (T)   |
|LIFE TABLE             |  P=0.201N     P=0.608      P=0.597      P=0.419N   |  P=0.129      P=0.530        (e)        P=0.231    |
|INCIDENTAL TUMOR       |  P=0.201N     P=0.608      P=0.597      P=0.419N   |  P=0.129      P=0.530        (e)        P=0.231    |
|LOGISTIC REGRESSION    |  P=0.201N     P=0.608      P=0.597      P=0.419N   |  P=0.129      P=0.530        (e)        P=0.231    |
|FISHER EXACT           |               P=0.500      P=0.506      P=0.496N   |               P=0.496        (e)        P=0.235    |
|     Carcinoma                                                                                |
|TERMINAL (d)           |  0/22 (0%)    1/30 (3%)    0/29 (0%)    1/33 (3%)  |  3/31 (10%)   1/36 (3%)    0/39 (0%)    1/30 (3%)  |
|FIRST INCIDENCE (DAYS) |   565          730 (T)      ---          730 (T)   |   737 (T)      647          ---          737 (T)   |
|LIFE TABLE             |  P=0.557N     P=0.726N     P=0.500N     P=0.722N   |  P=0.124N     P=0.572N     P=0.084N     P=0.316N   |
|INCIDENTAL TUMOR       |  P=0.501N     P=0.679N     P=0.500N     P=0.634N   |  P=0.131N     P=0.580N     P=0.084N     P=0.316N   |
|LOGISTIC REGRESSION    |  P=0.601N     P=0.762N     P=0.515N     P=0.758N   |  P=0.126N     P=0.609N     P=0.084N     P=0.316N   |
|FISHER EXACT           |               P=0.752N     P=0.496N     P=0.748N   |               P=0.652      P=0.122N     P=0.329N   |
|     Carcinoma or Adenoma                                                                                |
|ADJUSTED (b)           |   6.6%        10.0%         6.9%         3.0%      |   9.7%         9.7%         0.0%        10.0%      |
|TERMINAL (d)           |  1/22 (5%)    3/30 (10%)   2/29 (7%)    1/33 (3%)  |  3/31 (10%)   2/36 (6%)    0/39 (0%)    3/30 (10%) |
|FIRST INCIDENCE (DAYS) |   565          730 (T)      730 (T)      730 (T)   |   737 (T)      647          ---          737 (T)   |
|LIFE TABLE             |  P=0.207N     P=0.612      P=0.618N     P=0.412N   |  P=0.448N     P=0.598      P=0.084N     P=0.650    |
|INCIDENTAL TUMOR       |  P=0.185N     P=0.648      P=0.618N     P=0.330N   |  P=0.447N     P=0.592      P=0.084N     P=0.650    |
|LOGISTIC REGRESSION    |  P=0.281N     P=0.508      P=0.677N     P=0.493N   |  P=0.443N     P=0.570      P=0.084N     P=0.650    |
|FISHER EXACT           |               P=0.500      P=0.684N     P=0.494N   |               P=0.491      P=0.122N     P=0.636    |
|Islets, Pancreatic                                                                                |
|ADJUSTED (b)           |  10.9%         5.9%        15.7%        14.0%      |   0.0%         2.8%         2.6%         2.8%      |
|TERMINAL (d)           |  1/22 (5%)    1/31 (3%)    4/29 (14%)   3/33 (9%)  |  0/31 (0%)    1/36 (3%)    1/39 (3%)    0/31 (0%)  |
|FIRST INCIDENCE (DAYS) |   708          673          591          633       |   ---          737 (T)      737 (T)      707       |
|LIFE TABLE             |  P=0.281      P=0.429N     P=0.478      P=0.517    |  P=0.392      P=0.530      P=0.546      P=0.530    |
|INCIDENTAL TUMOR       |  P=0.192      P=0.639N     P=0.412      P=0.291    |  P=0.412      P=0.530      P=0.546      P=0.564    |
|LOGISTIC REGRESSION    |  P=0.203      P=0.473N     P=0.401      P=0.396    |  P=0.398      P=0.530      P=0.546      P=0.509    |
|COCHRAN-ARMITAGE       |  P=0.207                                           |  P=0.395                                           |
|FISHER EXACT           |               P=0.475N     P=0.388      P=0.398    |               P=0.496      P=0.500      P=0.500    |
|FIRST INCIDENCE (DAYS) |   612          ---          730 (T)      ---       |   ---          737 (T)      ---          ---       |
|LIFE TABLE             |  P=0.222N     P=0.205N     P=0.616N     P=0.198N   |  P=0.353N     P=0.272        (e)          (e)      |
|INCIDENTAL TUMOR       |  P=0.184N     P=0.135N     P=0.590N     P=0.106N   |  P=0.353N     P=0.272        (e)          (e)      |
|LOGISTIC REGRESSION    |  P=0.259N     P=0.226N     P=0.668N     P=0.224N   |  P=0.353N     P=0.272        (e)          (e)      |
|FISHER EXACT           |               P=0.235N     P=0.671N     P=0.231N   |               P=0.244        (e)          (e)      |
|OVERALL (a)            |  5/55 (9%)    2/58 (3%)    6/58 (10%)   5/59 (8%)  |  0/59 (0%)    3/58 (5%)    1/59 (2%)    1/59 (2%)  |
|LIFE TABLE             |  P=0.507      P=0.163N     P=0.607N     P=0.461N   |  P=0.613N     P=0.148      P=0.546      P=0.530    |
|INCIDENTAL TUMOR       |  P=0.438      P=0.237N     P=0.605      P=0.603N   |  P=0.597N     P=0.148      P=0.546      P=0.564    |
|LOGISTIC REGRESSION    |  P=0.406      P=0.195N     P=0.554      P=0.590N   |  P=0.602N     P=0.148      P=0.546      P=0.509    |
|FISHER EXACT           |               P=0.198N     P=0.538      P=0.583N   |               P=0.119      P=0.500      P=0.500    |
|     Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma                                                              |
|FIRST INCIDENCE (DAYS) |   ---          ---          ---          ---       |   645          737 (T)      737 (T)      737 (T)   |
|LIFE TABLE             |    (e)          (e)          (e)          (e)      |  P=0.510N     P=0.556      P=0.729N     P=0.746N   |
|INCIDENTAL TUMOR       |    (e)          (e)          (e)          (e)      |  P=0.502N     P=0.571      P=0.657      P=0.722N   |
|LOGISTIC REGRESSION    |    (e)          (e)          (e)          (e)      |  P=0.501N     P=0.537      P=0.754N     P=0.752N   |
|COCHRAN-ARMITAGE       |    (e)                                             |  P=0.512N                                          |
|FISHER EXACT           |                 (e)          (e)          (e)      |               P=0.500      P=0.752N     P=0.752N   |
|TUMOR RATES            |    #            #            #            #        |    #            #            #            #        |
|FIRST INCIDENCE (DAYS) |   ---          ---          ---          ---       |   589          713          ---          ---       |
|INCIDENTAL TUMOR       |    (e)          (e)          (e)          (e)      |  P=0.192N     P=0.292      P=0.669N     P=0.612N   |
|FIRST INCIDENCE (DAYS) |   ---          ---          ---          ---       |   589          713          668          ---       |
|LIFE TABLE             |    (e)          (e)          (e)          (e)      |  P=0.113N     P=0.641N     P=0.455N     P=0.231N   |
|LOGISTIC REGRESSION    |    (e)          (e)          (e)          (e)      |  P=0.117N     P=0.669N     P=0.496N     P=0.235N   |
|FISHER EXACT           |                 (e)          (e)          (e)      |               P=0.691N     P=0.500N     P=0.248N   |
|     Fibroadenoma                                                                                |
|OVERALL (a)            |  2/60 (3%)    3/60 (5%)    1/60 (2%)    0/60 (0%)  | 15/60 (25%)  19/60 (32%)  12/60 (20%)  11/60 (18%) |
|ADJUSTED (b)           |   7.6%         9.7%         3.4%         0.0%      |  45.2%        48.4%        29.8%        32.2%      |
|TERMINAL (d)           |  1/22 (5%)    3/31 (10%)   1/29 (3%)    0/33 (0%)  | 13/31 (42%)  16/36 (44%)  11/39 (28%)   9/32 (28%) |
|FIRST INCIDENCE (DAYS) |   703          730 (T)      730 (T)      ---       |   658          647          520          707       |
|LIFE TABLE             |  P=0.059N     P=0.632      P=0.416N     P=0.187N   |  P=0.080N     P=0.478      P=0.132N     P=0.203N   |
|INCIDENTAL TUMOR       |  P=0.076N     P=0.564      P=0.485N     P=0.304N   |  P=0.074N     P=0.496      P=0.185N     P=0.173N   |
|LOGISTIC REGRESSION    |  P=0.076N     P=0.553      P=0.464N     P=0.226N   |  P=0.066N     P=0.518      P=0.209N     P=0.150N   |
|FISHER EXACT           |               P=0.500      P=0.500N     P=0.248N   |               P=0.272      P=0.331N     P=0.253N   |
|     Fibroma, Fibroadenoma or Adenoma                                                                                |
|LIFE TABLE             |  P=0.059N     P=0.632      P=0.416N     P=0.187N   |  P=0.041N*    P=0.415      P=0.094N     P=0.149N   |
|INCIDENTAL TUMOR       |  P=0.076N     P=0.564      P=0.485N     P=0.304N   |  P=0.039N*    P=0.346      P=0.155N     P=0.138N   |
|LOGISTIC REGRESSION    |  P=0.076N     P=0.553      P=0.464N     P=0.226N   |  P=0.032N*    P=0.418      P=0.164N     P=0.109N   |
|     Fibroma, Fibroadenoma, Carcinoma, or Adenoma                                                                                |
|COCHRAN-ARMITAGE       |  P=0.094N                                          |  P=0.042N*                                         |
|FIRST INCIDENCE (DAYS) |   ---          580          ---          ---       |   ---          ---          ---          ---       |
|LIFE TABLE             |  P=0.321N     P=0.267        (e)          (e)      |    (e)          (e)          (e)          (e)      |
|INCIDENTAL TUMOR       |  P=0.275N     P=0.317        (e)          (e)      |    (e)          (e)          (e)          (e)      |
|LOGISTIC REGRESSION    |  P=0.351N     P=0.231        (e)          (e)      |    (e)          (e)          (e)          (e)      |
|COCHRAN-ARMITAGE       |  P=0.351N                                          |    (e)                                             |
|FISHER EXACT           |               P=0.239        (e)          (e)      |                 (e)          (e)          (e)      |
DATE: 09/16/94                     EXPERIMENT: 05127 TEST: 01                                                 PAGE  10
|ADJUSTED (b)           |  13.6%        12.9%         3.4%         9.1%      |   3.2%         0.0%         2.6%         0.0%      |
|TERMINAL (d)           |  3/22 (14%)   4/31 (13%)   1/29 (3%)    3/33 (9%)  |  1/31 (3%)    0/36 (0%)    1/39 (3%)    0/32 (0%)  |
|FIRST INCIDENCE (DAYS) |   730 (T)      730 (T)      730 (T)      730 (T)   |   737 (T)      ---          737 (T)      ---       |
|FISHER EXACT           |               P=0.530      P=0.283N     P=0.618N   |               P=0.509N     P=0.752N     P=0.496N   |
|FISHER EXACT           |               P=0.612N     P=0.161N     P=0.451N   |               P=0.509N     P=0.752N     P=0.496N   |
|Pituitary Gland: Pars Distalis or Unspecified Site                                                                               |
|OVERALL (a)            | 23/58 (40%)  25/55 (45%)  20/59 (34%)  23/56 (41%) | 30/58 (52%)  26/58 (45%)  30/59 (51%)  26/60 (43%) |
|ADJUSTED (b)           |  71.6%        56.7%        49.1%        54.0%      |  72.5%        61.5%        65.8%        58.9%      |
|INTERIM SACRIFICE 1 (c)|  2/10 (20%)   4/10 (40%)   3/10 (30%)   2/10 (20%) |  1/10 (10%)   0/10 (0%)    3/10 (30%)   2/10 (20%) |
|TERMINAL (d)           | 14/22 (64%)  12/29 (41%)  10/29 (34%)  14/32 (44%) | 20/31 (65%)  20/36 (56%)  23/38 (61%)  15/32 (47%) |
|FIRST INCIDENCE (DAYS) |   452 (I)      452 (I)      452 (I)      452 (I)   |   458 (I)      647          430          456 (I)   |
|INCIDENTAL TUMOR       |  P=0.435N     P=0.416      P=0.255N     P=0.384N   |  P=0.266N     P=0.294N     P=0.568      P=0.254N   |
|LOGISTIC REGRESSION    |  P=0.451N     P=0.346      P=0.288N     P=0.533    |  P=0.224N     P=0.287N     P=0.512N     P=0.190N   |
|FISHER EXACT           |               P=0.333      P=0.325N     P=0.515    |               P=0.289N     P=0.536N     P=0.233N   |
|OVERALL (a)            |  1/58 (2%)    1/55 (2%)    1/59 (2%)    2/56 (4%)  |  4/58 (7%)    6/58 (10%)   4/59 (7%)    5/60 (8%)  |
|TERMINAL (d)           |  1/22 (5%)    0/29 (0%)    0/29 (0%)    1/32 (3%)  |  4/31 (13%)   5/36 (14%)   4/38 (11%)   3/32 (9%)  |
|FIRST INCIDENCE (DAYS) |   730 (T)      723          528          620       |   737 (T)      428          737 (T)      669       |
|LIFE TABLE             |  P=0.402      P=0.688N     P=0.730N     P=0.583    |  P=0.538      P=0.458      P=0.528N     P=0.538    |
|INCIDENTAL TUMOR       |  P=0.316      P=0.722      P=0.696N     P=0.649    |  P=0.552      P=0.456      P=0.528N     P=0.559    |
|LOGISTIC REGRESSION    |  P=0.345      P=0.746N     P=0.763N     P=0.497    |  P=0.562N     P=0.418      P=0.528N     P=0.560    |
|FISHER EXACT           |               P=0.739      P=0.748N     P=0.487    |               P=0.371      P=0.632N     P=0.522    |
|INCIDENTAL TUMOR       |  P=0.527N     P=0.402      P=0.239N     P=0.412N   |  P=0.284N     P=0.317N     P=0.452N     P=0.285N   |
|     Basal Cell Carcinoma                                                                                |
|FIRST INCIDENCE (DAYS) |   730 (T)      ---          ---          730 (T)   |   ---          ---          ---          ---       |
|LIFE TABLE             |  P=0.295      P=0.432N     P=0.445N     P=0.641    |    (e)          (e)          (e)          (e)      |
|INCIDENTAL TUMOR       |  P=0.295      P=0.432N     P=0.445N     P=0.641    |    (e)          (e)          (e)          (e)      |
|LOGISTIC REGRESSION    |  P=0.295      P=0.432N     P=0.445N     P=0.641    |    (e)          (e)          (e)          (e)      |
|COCHRAN-ARMITAGE       |  P=0.232                                           |    (e)                                             |
|FISHER EXACT           |               P=0.500N     P=0.500N     P=0.500    |                 (e)          (e)          (e)      |
|     Fibroma                                                                                |
|ADJUSTED (b)           |   0.0%         0.0%         3.4%         2.9%      |  12.9%         2.8%         0.0%         2.8%      |
|FIRST INCIDENCE (DAYS) |   ---          ---          730 (T)      726       |   737 (T)      737 (T)      ---          707       |
|LIFE TABLE             |  P=0.280        (e)        P=0.555      P=0.587    |  P=0.103N     P=0.136N     P=0.038N*    P=0.165N   |
|INCIDENTAL TUMOR       |  P=0.166        (e)        P=0.555      P=0.261    |  P=0.108N     P=0.136N     P=0.038N*    P=0.155N   |
|LOGISTIC REGRESSION    |  P=0.250        (e)        P=0.555      P=0.532    |  P=0.101N     P=0.136N     P=0.038N*    P=0.149N   |
|FISHER EXACT           |                 (e)        P=0.500      P=0.500    |               P=0.182N     P=0.059N     P=0.182N   |
|     Keratoacanthoma                                                                                |
|TERMINAL (d)           |  0/22 (0%)    3/31 (10%)   0/29 (0%)    0/33 (0%)  |  0/31 (0%)    1/36 (3%)    1/39 (3%)    0/32 (0%)  |
|FIRST INCIDENCE (DAYS) |   712          730 (T)      ---          ---       |   ---          737 (T)      737 (T)      ---       |
|LIFE TABLE             |  P=0.090N     P=0.424      P=0.459N     P=0.446N   |  P=0.577N     P=0.530      P=0.546        (e)      |
|INCIDENTAL TUMOR       |  P=0.122N     P=0.334      P=0.586N     P=0.739N   |  P=0.577N     P=0.530      P=0.546        (e)      |
|LOGISTIC REGRESSION    |  P=0.109N     P=0.350      P=0.487N     P=0.493N   |  P=0.577N     P=0.530      P=0.546        (e)      |
|FISHER EXACT           |               P=0.309      P=0.500N     P=0.500N   |               P=0.500      P=0.500        (e)      |
|     Squamous Cell Carcinoma, Papilloma Squamous, or Papilloma                                                                   |
|FIRST INCIDENCE (DAYS) |   ---          ---          ---          ---       |   645          ---          ---          650       |
|INCIDENTAL TUMOR       |    (e)          (e)          (e)          (e)      |  P=0.464N     P=0.190N     P=0.343N     P=0.422N   |
|     Trichoepithelioma, Basal Cell Carcinoma, or Basal Cell Adenoma                                                              |
|FIRST INCIDENCE (DAYS) |   730 (T)      ---          704          730 (T)   |   ---          ---          ---          ---       |
|LIFE TABLE             |  P=0.527      P=0.166N     P=0.412N     P=0.542N   |    (e)          (e)          (e)          (e)      |
|INCIDENTAL TUMOR       |  P=0.458      P=0.166N     P=0.485N     P=0.542N   |    (e)          (e)          (e)          (e)      |
|LOGISTIC REGRESSION    |  P=0.470      P=0.166N     P=0.463N     P=0.542N   |    (e)          (e)          (e)          (e)      |
|FISHER EXACT           |               P=0.248N     P=0.500N     P=0.691N   |                 (e)          (e)          (e)      |
|     Trichoepithelioma, Kertatocanthoma, Squamous Cell Carcinoma,                                                                |
|     Basal Cell Carcinoma or Adenoma, Papilloma Squamous, or Papilloma                                                           |
|ADJUSTED (b)           |  12.6%         9.7%         2.7%         6.1%      |   5.7%         2.8%         2.6%         2.4%      |
|FIRST INCIDENCE (DAYS) |   712          730 (T)      704          730 (T)   |   645          737 (T)      737 (T)      650       |
|     Squamous Cell Papilloma                                                                                |
|FIRST INCIDENCE (DAYS) |   ---          673          452 (I)      ---       |   692          ---          310          ---       |
|LIFE TABLE             |  P=0.405N     P=0.266      P=0.500        (e)      |  P=0.478N     P=0.443N     P=0.530      P=0.472N   |
|INCIDENTAL TUMOR       |  P=0.588N     P=0.102      P=0.500        (e)      |  P=0.599N     P=0.436N     P=0.263      P=0.436N   |
|LOGISTIC REGRESSION    |  P=0.422N     P=0.242      P=0.417        (e)      |  P=0.512N     P=0.486N     P=0.492      P=0.490N   |
|FISHER EXACT           |               P=0.248      P=0.500        (e)      |               P=0.500N     P=0.500      P=0.500N   |
|Testes                                                                                |
|OVERALL (a)            | 43/59 (73%)  48/60 (80%)  50/60 (83%)  44/60 (73%) |                                                    |
|ADJUSTED (b)           |  91.1%        95.9%       100.0%        93.3%      |                                                    |
|INTERIM SACRIFICE 1 (c)|  4/10 (40%)   4/10 (40%)   4/10 (40%)   7/10 (70%) |                                                    |
|TERMINAL (d)           | 18/22 (82%)  29/31 (94%)  29/29 (100%) 30/33 (91%) |                                                    |
|FIRST INCIDENCE (DAYS) |   452 (I)      452 (I)      452 (I)      452 (I)   |                                                    |
|LIFE TABLE             |  P=0.085N     P=0.349N     P=0.468N     P=0.092N   |                                                    |
|INCIDENTAL TUMOR       |  P=0.487N     P=0.256      P=0.095      P=0.562N   |                                                    |
|LOGISTIC REGRESSION    |  P=0.515N     P=0.258      P=0.129      P=0.555    |                                                    |
|COCHRAN-ARMITAGE       |  P=0.483N                                          |                                                    |
|FISHER EXACT           |               P=0.242      P=0.123      P=0.560    |                                                    |
|OVERALL (a)            |  5/59 (8%)    5/58 (9%)    8/60 (13%)   8/60 (13%) |  6/59 (10%)   8/60 (13%)  10/60 (17%)  10/60 (17%) |
|INTERIM SACRIFICE 1 (c)|  0/10 (0%)    0/10 (0%)    1/10 (10%)   0/10 (0%)  |  1/10 (10%)   0/10 (0%)    1/10 (10%)   1/10 (10%) |
|TERMINAL (d)           |  1/22 (5%)    5/31 (16%)   4/29 (14%)   8/33 (24%) |  4/31 (13%)   4/36 (11%)   8/39 (21%)   7/32 (22%) |
|FIRST INCIDENCE (DAYS) |   565          730 (T)      453 (I)      730 (T)   |   456 (I)      647          458 (I)      458 (I)   |
|FISHER EXACT           |               P=0.618      P=0.290      P=0.290    |               P=0.402      P=0.221      P=0.221    |
|OVERALL (a)            |  5/59 (8%)    6/58 (10%)   8/60 (13%)   9/60 (15%) |  6/59 (10%)   8/60 (13%)  10/60 (17%)  10/60 (17%) |
|FIRST INCIDENCE (DAYS) |   565          723          453 (I)      564       |   456 (I)      647          458 (I)      458 (I)   |
|INCIDENTAL TUMOR       |  P=0.186      P=0.522      P=0.287      P=0.354    |  P=0.196      P=0.439      P=0.315      P=0.221    |
|LOGISTIC REGRESSION    |  P=0.147      P=0.508      P=0.294      P=0.208    |  P=0.192      P=0.452      P=0.236      P=0.238    |
|FIRST INCIDENCE (DAYS) |   ---          ---          453 (I)      730 (T)   |   ---          ---          ---          ---       |
|LIFE TABLE             |  P=0.274        (e)        P=0.270      P=0.581    |    (e)          (e)          (e)          (e)      |
|INCIDENTAL TUMOR       |  P=0.274        (e)        P=0.270      P=0.581    |    (e)          (e)          (e)          (e)      |
|LOGISTIC REGRESSION    |  P=0.238        (e)        P=0.228      P=0.581    |    (e)          (e)          (e)          (e)      |
|FISHER EXACT           |                 (e)        P=0.252      P=0.504    |                 (e)          (e)          (e)      |
|FIRST INCIDENCE (DAYS) |   730 (T)      ---          453 (I)      730 (T)   |   692          737 (T)      ---          ---       |
|LIFE TABLE             |  P=0.540      P=0.432N     P=0.564      P=0.669N   |  P=0.217N     P=0.711N     P=0.467N     P=0.472N   |
|INCIDENTAL TUMOR       |  P=0.540      P=0.432N     P=0.564      P=0.669N   |  P=0.217N     P=0.693N     P=0.748N     P=0.410N   |
|LOGISTIC REGRESSION    |  P=0.481      P=0.432N     P=0.502      P=0.669N   |  P=0.217N     P=0.732N     P=0.489N     P=0.487N   |
|FISHER EXACT           |               P=0.504N     P=0.506      P=0.748N   |               P=0.748N     P=0.496N     P=0.496N   |
|     Polyp Stromal                                                                                |
|TUMOR RATES            |                                                    |    #            #            #            #        |
|OVERALL (a)            |                                                    | 15/60 (25%)   8/60 (13%)  11/60 (18%)  16/60 (27%) |
|ADJUSTED (b)           |                                                    |  36.8%        21.5%        26.2%        40.1%      |
|INTERIM SACRIFICE 1 (c)|                                                    |  2/10 (20%)   0/10 (0%)    1/10 (10%)   2/10 (20%) |
|TERMINAL (d)           |                                                    |  8/31 (26%)   7/36 (19%)   9/39 (23%)  10/32 (31%) |
|FIRST INCIDENCE (DAYS) |                                                    |   456 (I)      707          456 (I)      456 (I)   |
|LIFE TABLE             |                                                    |  P=0.258      P=0.044N*    P=0.136N     P=0.551    |
|INCIDENTAL TUMOR       |                                                    |  P=0.251      P=0.089N     P=0.264N     P=0.521    |
|LOGISTIC REGRESSION    |                                                    |  P=0.265      P=0.063N     P=0.234N     P=0.529    |
|COCHRAN-ARMITAGE       |                                                    |  P=0.250                                           |
|FISHER EXACT           |                                                    |               P=0.082N     P=0.253N     P=0.500    |
|     Sarcoma Stromal                                                                                |
|OVERALL (a)            |                                                    |  0/60 (0%)    2/60 (3%)    1/60 (2%)    0/60 (0%)  |
|ADJUSTED (b)           |                                                    |   0.0%         5.6%         2.3%         0.0%      |
|INTERIM SACRIFICE 1 (c)|                                                    |  0/10 (0%)    0/10 (0%)    0/10 (0%)    0/10 (0%)  |
|TERMINAL (d)           |                                                    |  0/31 (0%)    2/36 (6%)    0/39 (0%)    0/32 (0%)  |
|FIRST INCIDENCE (DAYS) |                                                    |   ---          737 (T)      627          ---       |
|LIFE TABLE             |                                                    |  P=0.418N     P=0.272      P=0.519        (e)      |
|INCIDENTAL TUMOR       |                                                    |  P=0.444N     P=0.272      P=0.331        (e)      |
|LOGISTIC REGRESSION    |                                                    |  P=0.417N     P=0.272      P=0.497        (e)      |
|COCHRAN-ARMITAGE       |                                                    |  P=0.424N                                          |
|FISHER EXACT           |                                                    |               P=0.248      P=0.500        (e)      |
|     Sarcoma Stromal or Polyp Stromal                                                                                |
|OVERALL (a)            |                                                    | 15/60 (25%)  10/60 (17%)  12/60 (20%)  16/60 (27%) |
|LIFE TABLE             |                                                    |  P=0.317      P=0.105N     P=0.191N     P=0.551    |
|Zymbal's Gland                                                                                |
|FIRST INCIDENCE (DAYS) |   ---          544          520          582       |   575          ---          ---          644       |
|LIFE TABLE             |  P=0.267      P=0.244      P=0.504      P=0.240    |  P=0.578      P=0.496N     P=0.509N     P=0.747N   |
|INCIDENTAL TUMOR       |  P=0.328      P=0.284      P=0.557      P=0.397    |  P=0.524        (e)        P=0.669N     P=0.638    |
|LOGISTIC REGRESSION    |  P=0.272      P=0.226      P=0.467      P=0.239    |  P=0.568      P=0.524N     P=0.505N     P=0.750    |
|FISHER EXACT           |               P=0.248      P=0.500      P=0.248    |               P=0.500N     P=0.500N     P=0.752N   |
|All Organs                                                                                |
|     Leukemia: Lymphocytic, Monocytic, Mononuclear,                                                                              |
|     or Undifferentiated                                                                                |
|OVERALL (a)            | 35/60 (58%)  25/60 (42%)  26/60 (43%)  15/60 (25%) | 15/60 (25%)  13/60 (22%)   9/60 (15%)   9/60 (15%) |
|TERMINAL (d)           |  9/22 (41%)  13/31 (42%)  12/29 (41%)   8/33 (24%) |  7/31 (23%)   8/36 (22%)   5/39 (13%)   5/32 (16%) |
|FIRST INCIDENCE (DAYS) |   305          520          590          564       |   359          666          462          493       |
|LIFE TABLE             |  P<0.001N**   P=0.031N*    P=0.036N*    P<0.001N** |  P=0.080N     P=0.246N     P=0.074N     P=0.111N   |
|INCIDENTAL TUMOR       |  P=0.003N**   P=0.140N     P=0.200N     P=0.010N** |  P=0.075N     P=0.559N     P=0.237N     P=0.154N   |
|LOGISTIC REGRESSION    |  P<0.001N**   P=0.040N*    P=0.056N     P<0.001N** |  P=0.073N     P=0.349N     P=0.123N     P=0.112N   |
|COCHRAN-ARMITAGE       |  P<0.001N**                                        |  P=0.082N                                          |
|FISHER EXACT           |               P=0.050N*    P=0.072N     P<0.001N** |               P=0.415N     P=0.127N     P=0.127N   |
|     Benign Tumors                                                                                |
|ADJUSTED (b)           |  98.1%       100.0%       100.0%       100.0%      |  93.8%        88.6%        85.6%        83.9%      |
|TERMINAL (d)           | 21/22 (95%)  31/31 (100%) 29/29 (100%) 33/33 (100%)| 28/31 (90%)  31/36 (86%)  32/39 (82%)  24/32 (75%) |
|LIFE TABLE             |  P=0.046N*    P=0.299N     P=0.279N     P=0.050N*  |  P=0.449N     P=0.013N*    P=0.054N     P=0.261N   |
|INCIDENTAL TUMOR       |  P=0.304N     P=0.113      P=0.187      P=0.482N   |  P=0.468N     P=0.017N*    P=0.331N     P=0.245N   |
|LOGISTIC REGRESSION    |  P=0.418N     P=0.114      P=0.218      P=0.585    |  P=0.394N     P=0.010N*    P=0.273N     P=0.214N   |
|FISHER EXACT           |               P=0.102      P=0.181      P=0.605N   |               P=0.114N     P=0.339N     P=0.339N   |
|     Malignant Tumors                                                                                |
|INTERIM SACRIFICE 1 (c)|  0/10 (0%)    0/10 (0%)    1/10 (10%)   0/10 (0%)  |  0/10 (0%)    0/10 (0%)    1/10 (10%)   1/10 (10%) |
|TERMINAL (d)           | 11/22 (50%)  14/31 (45%)  15/29 (52%)  14/33 (42%) | 13/31 (42%)  17/36 (47%)   9/39 (23%)  11/32 (34%) |
|FIRST INCIDENCE (DAYS) |   305          520          453 (I)      564       |   359          428          458 (I)      458 (I)   |
|LIFE TABLE             |  P=0.017N*    P=0.015N*    P=0.128N     P=0.005N** |  P=0.123N     P=0.295N     P=0.014N*    P=0.194N   |
|INCIDENTAL TUMOR       |  P=0.081N     P=0.042N*    P=0.573N     P=0.044N*  |  P=0.086N     P=0.552      P=0.112N     P=0.212N   |
|LOGISTIC REGRESSION    |  P=0.043N*    P=0.014N*    P=0.284N     P=0.010N** |  P=0.086N     P=0.485N     P=0.026N*    P=0.190N   |
|COCHRAN-ARMITAGE       |  P=0.032N*                                         |  P=0.112N                                          |
|FISHER EXACT           |               P=0.022N*    P=0.287N     P=0.009N** |               P=0.573N     P=0.028N*    P=0.229N   |
|     Malignant and Benign Tumors                                                                                |
|ADJUSTED (b)           | 100.0%       100.0%       100.0%       100.0%      |  96.2%        89.8%        88.8%        94.3%      |
|TERMINAL (d)           | 22/22 (100%) 31/31 (100%) 29/29 (100%) 33/33 (100%)| 29/31 (94%)  31/36 (86%)  33/39 (85%)  29/32 (91%) |
|FIRST INCIDENCE (DAYS) |   305          452 (I)      452 (I)      452 (I)   |   359          428          310          456 (I)   |
|LIFE TABLE             |  P=0.110N     P=0.136N     P=0.235N     P=0.079N   |  P=0.480      P=0.018N*    P=0.063N     P=0.354N   |
|INCIDENTAL TUMOR       |  P=0.380      P=0.500      P=0.157      P=0.533    |  P=0.380      P=0.042N*    P=0.376N     P=0.509N   |
|LOGISTIC REGRESSION    |  P=0.261      P=0.647      P=0.253      P=0.435    |  P=0.493      P=0.016N*    P=0.274N     P=0.343N   |
(a)  Number of tumor-bearing animals / number of animals examined at site.
(b)  Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(c)  Observed incidence at interim kill.
Male interim sacrifices(days):   452
Female interim sacrifices(days): 456
table analysis regards tumors in animals dying  prior to terminal kill as
being (directly or indirectly) the cause of death.  The incidental tumor
test regards these lesions as non-fatal.  Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors.  The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".


text:
Ship Management International column March/April 2018 - Watch out, there's a thief about!
To see the article as it appears in Ship Management International please click here (page 10)
The increased incidence of fraud – and how to detect, minimise and prevent it – has been the focus of extensive recent discussion in the maritime sector. Cyber-crime has dominated much of the debate, but ship managers should be aware that the problem of fraud is not limited to crimes perpetrated by criminals from outside their organisation gaining access to their systems.
Although securing protection against ransomware and other cyber-threats is of vital importance, this should not blind ship managers to the possibility of frauds perpetrated by individuals within their own organisations.
ITIC has seen a wide variety of frauds, all of which have one thing in common – they involve criminals seeking to extort money. A common feature is for the criminals to arrange for their victims to pay more than they need to, and then keep the difference for themselves.
A simple example was a fraud run for a number of years by an executive in a ship manager's purchasing department. He arranged for goods to be supplied by 'his contacts'. In fact, the invoices came from a company he had created, and were for slightly inflated prices. He ordered the goods from genuine suppliers, and the suppliers invoiced the address they were given in the correct amount. He then paid them out of the money he had received and pocketed the difference.
Repeated small frauds of this type often add up to significant sums over time and can be difficult to spot. Often it is an unexpected event (in this case a dispute over a defect in the goods supplied) that brings the fraud to light. When the fraudster is exposed, other staff members invariably say that the individual was unusually sensitive about any queries in connection with 'his business', always insisting that he would sort them out himself.
Another fraud seen by ITIC involved an unexpected staff absence leading to the discovery of a fleet manager who was engaged in 'ghost payrolling'. This employee created a fictitious officer whom he 'deployed' on various ships in the managed fleet. The payroll had been outsourced to an external company, and the fleet manager insisted that only he would sign off the crew payrolls – something which, on reflection, the shipmanagement company admitted was strange for someone of his seniority. It did however enable him to arrange payments to the fictitious officer without scrutiny. By deploying 'his officer' across the fleet, the additional costs fell on different owners. Once the fraud was uncovered it was realised that, for a short period, 'his officer' had supposedly been 'working' on two ships in the managed fleet.
Elsewhere, crew payments in cash proved too tempting for an employee of a ship manager in the Far East. An investigation prompted by the discovery of large discrepancies in one of the managed fleet's accounts revealed that one of the crewing team had a very simple scam going on involving the issuing of inflated fund requests for final salaries of seafarers signing off from ships. The fund requests were presented to the accounting team, who issued the salaries in cash.
The crewing executive put the correct amount of cash into sealed envelopes for visiting superintendent to pass to the Master of the ship and kept the balance created by the inflated fund request. The superintendent brought back the acknowledgement receipts from the seafarers, whereupon the member ofthe crewing team recorded the crew as having received the higher amounts and disposed of the actual receipts. Over time, $900,000 had been stolen.
A lesson drawn from these accounting frauds is to be careful to avoid an individual having the ability to control every aspect of a transaction with minimal scrutiny. It may be worth ship managers having a review of the systems and controls in their business to minimise the risk of fraud.
Watch out, there's a thief about! (364 kB)

redpajama_set_name: RedPajamaCommonCrawl


This entry was posted	on Tuesday, September 9th, 2008 at 10:04 pm	by james and is filed under Emily.	You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Nice pic – Sophie has her hands full – that's a big baby girl!


JOSE MOURINHO and Sam Allardyce have joined forces to plead for Manchester City not to sack Manuel Pellegrini.
Chilean Pellegrini is under severe pressure at City, with his club having dropped out of the defence of their Premier League title after a run of just two wins in six games.
Real Madrid coach Carlo Ancelotti is rated as a possible successor as Pellegrini's position becomes more precarious.
But Chelsea manager Mourinho yesterday slammed the way that Pellegrini is being treated like a "criminal" and said: "What has happened to City can happen to anyone.
"Do they not deserve respect, are they bad players, is the manager ia bad manager, are they a disaster?
"But they are the champions. I don't understand. On the one hand you want competitiveness. But people don't like a team to win two titles in a row, a team to be dominant. They want lots of teams fighting for the title.
West Ham manager Allardyce, whose side face City at the Etihad tomorrow, also leapt to Pellegrini's defence, saying: "The hardest thing to do in football is to win the title back-to-back.
"City won it fair and square last year and found it hard to raise themselves to that level again.
Only three managers – Bob Paisley at Liverpool, Sir Alex Ferguson at Manchester United and Mourinho at Chelsea – have won back to back titles in the last 50 years.


Whether you are a pilot or support personnel the Corporate Aviation Management Certificate (CAMC) program will prepare you to advance to a management role within your organization or take you to new heights in Business Aviation for a change in careers.
Approved by the National Business Aviation Association (NBAA), our CAMC program contains a total of 23 online courses and awards points towards the NBAA's Certified Aviation Manager (CAM) designation as well as their Professional Development and Schedulers and Dispatchers Professional Development programs (PDP/SPDP). You may also earn points for CAM renewal. For more information on CAM and PDP/SPDP visit www.nbaa.org.
CAMC is run on a monthly schedule. Each course runs 30 to 60 days in length and is facilitated by an instructor. There are no scheduled class times or live sessions to attend so it will definitely accommodate your busy work and travel schedule. Each online course is all inclusive with web based delivery, so no text books or special software to buy, all you need is a reliable high speed internet connection to access your courses at your convenience.


text:
import { Disposable, DisposableStore } from 'vs/base/common/lifecycle';
import { EditorInput, EditorOptions, IVisibleEditorPane } from 'vs/workbench/common/editor';
import { Dimension, show, hide, addClass } from 'vs/base/browser/dom';
import { Registry } from 'vs/platform/registry/common/platform';
import { IEditorRegistry, Extensions as EditorExtensions, IEditorDescriptor } from 'vs/workbench/browser/editor';
import { IWorkbenchLayoutService } from 'vs/workbench/services/layout/browser/layoutService';
import { BaseEditor } from 'vs/workbench/browser/parts/editor/baseEditor';
import { IInstantiationService } from 'vs/platform/instantiation/common/instantiation';
import { IEditorProgressService, LongRunningOperation } from 'vs/platform/progress/common/progress';
import { IEditorGroupView, DEFAULT_EDITOR_MIN_DIMENSIONS, DEFAULT_EDITOR_MAX_DIMENSIONS } from 'vs/workbench/browser/parts/editor/editor';
import { Emitter } from 'vs/base/common/event';
import { assertIsDefined } from 'vs/base/common/types';

export interface IOpenEditorResult {
	readonly editorPane: BaseEditor;
	readonly editorChanged: boolean;
}

export class EditorControl extends Disposable {

	get minimumWidth() { return this._activeEditorPane?.minimumWidth ?? DEFAULT_EDITOR_MIN_DIMENSIONS.width; }
	get minimumHeight() { return this._activeEditorPane?.minimumHeight ?? DEFAULT_EDITOR_MIN_DIMENSIONS.height; }
	get maximumWidth() { return this._activeEditorPane?.maximumWidth ?? DEFAULT_EDITOR_MAX_DIMENSIONS.width; }
	get maximumHeight() { return this._activeEditorPane?.maximumHeight ?? DEFAULT_EDITOR_MAX_DIMENSIONS.height; }

	private readonly _onDidFocus = this._register(new Emitter<void>());
	readonly onDidFocus = this._onDidFocus.event;

	private _onDidSizeConstraintsChange = this._register(new Emitter<{ width: number; height: number; } | undefined>());
	readonly onDidSizeConstraintsChange = this._onDidSizeConstraintsChange.event;

	private _activeEditorPane: BaseEditor | null = null;
	get activeEditorPane(): IVisibleEditorPane | null { return this._activeEditorPane as IVisibleEditorPane | null; }

	private readonly editorPanes: BaseEditor[] = [];

	private readonly activeEditorPaneDisposables = this._register(new DisposableStore());
	private dimension: Dimension | undefined;
	private readonly editorOperation = this._register(new LongRunningOperation(this.editorProgressService));

	constructor(
		private parent: HTMLElement,
		private groupView: IEditorGroupView,
		@IWorkbenchLayoutService private readonly layoutService: IWorkbenchLayoutService,
		@IInstantiationService private readonly instantiationService: IInstantiationService,
		@IEditorProgressService private readonly editorProgressService: IEditorProgressService
	) {
		super();
	}

	async openEditor(editor: EditorInput, options?: EditorOptions): Promise<IOpenEditorResult> {

		// Editor pane
		const descriptor = Registry.as<IEditorRegistry>(EditorExtensions.Editors).getEditor(editor);
		if (!descriptor) {
			throw new Error(`No editor descriptor found for input id ${editor.getTypeId()}`);
		}
		const editorPane = this.doShowEditorPane(descriptor);

		// Set input
		const editorChanged = await this.doSetInput(editorPane, editor, options);
		return { editorPane, editorChanged };
	}

	private doShowEditorPane(descriptor: IEditorDescriptor): BaseEditor {

		// Return early if the currently active editor pane can handle the input
		if (this._activeEditorPane && descriptor.describes(this._activeEditorPane)) {
			return this._activeEditorPane;
		}

		// Hide active one first
		this.doHideActiveEditorPane();

		// Create editor pane
		const editorPane = this.doCreateEditorPane(descriptor);

		// Set editor as active
		this.doSetActiveEditorPane(editorPane);

		// Show editor
		const container = assertIsDefined(editorPane.getContainer());
		this.parent.appendChild(container);
		show(container);

		// Indicate to editor that it is now visible
		editorPane.setVisible(true, this.groupView);

		// Layout
		if (this.dimension) {
			editorPane.layout(this.dimension);
		}

		return editorPane;
	}

	private doCreateEditorPane(descriptor: IEditorDescriptor): BaseEditor {

		// Instantiate editor
		const editorPane = this.doInstantiateEditorPane(descriptor);

		// Create editor container as needed
		if (!editorPane.getContainer()) {
			const editorPaneContainer = document.createElement('div');
			addClass(editorPaneContainer, 'editor-instance');
			editorPaneContainer.setAttribute('data-editor-id', descriptor.getId());

			editorPane.create(editorPaneContainer);
		}

		return editorPane;
	}

	private doInstantiateEditorPane(descriptor: IEditorDescriptor): BaseEditor {

		// Return early if already instantiated
		const existingEditorPane = this.editorPanes.find(editorPane => descriptor.describes(editorPane));
		if (existingEditorPane) {
			return existingEditorPane;
		}

		// Otherwise instantiate new
		const editorPane = this._register(descriptor.instantiate(this.instantiationService));
		this.editorPanes.push(editorPane);

		return editorPane;
	}

	private doSetActiveEditorPane(editorPane: BaseEditor | null) {
		this._activeEditorPane = editorPane;

		// Clear out previous active editor pane listeners
		this.activeEditorPaneDisposables.clear();

		// Listen to editor pane changes
		if (editorPane) {
			this.activeEditorPaneDisposables.add(editorPane.onDidSizeConstraintsChange(e => this._onDidSizeConstraintsChange.fire(e)));
			this.activeEditorPaneDisposables.add(editorPane.onDidFocus(() => this._onDidFocus.fire()));
		}

		// Indicate that size constraints could have changed due to new editor
		this._onDidSizeConstraintsChange.fire(undefined);
	}

	private async doSetInput(editorPane: BaseEditor, editor: EditorInput, options: EditorOptions | undefined): Promise<boolean> {

		// If the input did not change, return early and only apply the options
		// unless the options instruct us to force open it even if it is the same
		const forceReload = options?.forceReload;
		const inputMatches = editorPane.input && editorPane.input.matches(editor);
		if (inputMatches && !forceReload) {

			// Forward options
			editorPane.setOptions(options);

			// Still focus as needed
			const focus = !options || !options.preserveFocus;
			if (focus) {
				editorPane.focus();
			}

			return false;
		}

		// Show progress while setting input after a certain timeout. If the workbench is opening
		// be more relaxed about progress showing by increasing the delay a little bit to reduce flicker.
		const operation = this.editorOperation.start(this.layoutService.isRestored() ? 800 : 3200);

		// Call into editor pane
		const editorWillChange = !inputMatches;
		try {
			await editorPane.setInput(editor, options, operation.token);

			// Focus (unless prevented or another operation is running)
			if (operation.isCurrent()) {
				const focus = !options || !options.preserveFocus;
				if (focus) {
					editorPane.focus();
				}
			}

			return editorWillChange;
		} finally {
			operation.stop();
		}
	}

	private doHideActiveEditorPane(): void {
		if (!this._activeEditorPane) {
			return;
		}

		// Stop any running operation
		this.editorOperation.stop();

		// Indicate to editor pane before removing the editor from
		// the DOM to give a chance to persist certain state that
		// might depend on still being the active DOM element.
		this._activeEditorPane.clearInput();
		this._activeEditorPane.setVisible(false, this.groupView);

		// Remove editor pane from parent
		const editorPaneContainer = this._activeEditorPane.getContainer();
		if (editorPaneContainer) {
			this.parent.removeChild(editorPaneContainer);
			hide(editorPaneContainer);
		}

		// Clear active editor pane
		this.doSetActiveEditorPane(null);
	}

	closeEditor(editor: EditorInput): void {
		if (this._activeEditorPane && editor.matches(this._activeEditorPane.input)) {
			this.doHideActiveEditorPane();
		}
	}

	setVisible(visible: boolean): void {
		this._activeEditorPane?.setVisible(visible, this.groupView);
	}

	layout(dimension: Dimension): void {
		this.dimension = dimension;

		this._activeEditorPane?.layout(dimension);
	}
}

redpajama_set_name: RedPajamaGithub


Don't cry over broke crockery.
In Old Germanic tradition, broken pottery is thought to bring good luck. And so it can—if you can find a way to recycle it back onto the center table. Made from broken plates, vases, and teapots, this practical trivet can't help but coordinate perfectly with your tableware. It's an easy, fun, absolutely kid-friendly project that can take a little of the sting out of those kitchen crashes.
1. You'll want pottery pieces that are 1 or 2 inches in size. If yours are too big, place them in the paper bag and hit it sharply with a hammer.
2. Fill the tin lid 3/4 full with the wet plaster, then set the pieces into the surface.
3. Let the plaster set up for a few minutes, then smooth the plaster in the crevices and clean off the pottery faces with the wet sponge.
5. If there's a thin film of plaster on the pottery surfaces, carefully wipe it away with a clean cloth.


text:
iPhone XS teardown shows single-cell battery, few other changes from iPhone X
While the iPhone XS shares the practically the same external appearance as the iPhone X, the first teardown of the latest Apple smartphone reveals a few changes were made to the inside, including the use of a new battery and some smaller alterations to other internal components.
The customary teardown of the iPhone XS, this time by FixjeiPhone, appears at first glance to be the same as the iPhone X's treatment last year. From the outset, however, the technician disassembling the device notes it is harder to gain access, with the screen a little tougher to remove than before because of its watertight seal, which helps the iPhone X have an improved IP68 water resistance rating.
Putting the iPhone XS and iPhone X side by side, the general appearance of the internals are quite similar to one another, with components residing in the newer iPhone in the same place as they were in the year-old model.
One obvious change to the design is the battery, switching out the two-cell L-shaped battery in the iPhone X for a single-cell version, one which retains the same shape but appears to be marginally smaller in size. It was previously revealed the iPhone XS has a 2,658mAh battery in a regulatory filing, smaller than the iPhone X's 2,716mAh version, but power efficiency savings offer a claimed extra 30 minutes of usage time in the new version.
A less obvious change is the camera module in the top right corner of the device, with the top section of the component appearing to be bigger than in the iPhone X. The upper wide-angle camera has been updated to have a bigger pixel pitch in the sensor by 20 percent, to aid with light sensitivity, causing the change in module size.
The camera change does not only affect the internal space, as it has also increased the size of the camera hump by a few millimeters, potentially causing issues with customers wanting to reuse their iPhone X case with the iPhone XS.
Ultimately, the internal construction of the iPhone XS reuses the majority of the design of the iPhone X, which is unsurprising considering the similarity between the two devices.
More teardowns and other disassembly reports anticipated in the coming days may provide more clues to the smaller changes in the new iPhone, including the sourcing of its components.
ndnyc
"it has also increased the size of the camera hump by a few millimeters" 1.37 is not "a few"
The battery in the XS has an Apple logo on it. That typically means Apple designed the component, or some significant portion of it, and contracted out the manufacture of the battery. In the X, no Apple logos on the batteries.
The need to tear down the PCB and other components for other changes. There's probably a new touchscreen driver chip, new speaker driver chip, modem, antennas, etc.
I believe there is a typo.
Should be iPhone XS has IP68. The iPhone X has IP67.
macxpress
tht said:
I thought Apple pretty much designed all of its batteries?
macxpress said:
Maybe. I don't know for sure. But an Apple logo appearing on the package signifies Apple ownership of that product. I don't think I've seen an Apple logo on a battery in an Apple device before.
The logo definitely signifies that the battery is their design. It's strange to even see it on a battery as it seems to be one of those easily compartmentalized components that major battery makes can do.
By Christine McKee | 1 hour ago
Apple has appointed company veteran and long-time spokesperson Kristin Huguet as its vice president of worldwide communications, replacing Stella Low.
By Mike Peterson | 15 hours ago
Senate Judiciary Committee advances antitrust bill targeting Big Tech
A bipartisan antitrust bill aimed at stopping tech giants from "self-preferencing" their own products and services on platforms they own is headed for a vote before the full Senate.


I'm happy to have completed this sweater and it fits perfect. I was ectastic about the striping once I completed the back because there wasn't any pooling, but as I neared the front top part, I ended up with large blocks of stripes. Pattern Description: Strawberry Pullover V-neck Sweater knitted in rev st st.
Did it look like the photo in the Magazine: As for the style design, it looks like the photo.
Were the instructions easy to follow: The instructions were straight forward.
Pattern Alterations or any design changes you made: I opted for a variegated yarn. I had to modify the cast-on stitches, although I swatched. The pattern called for casting-on 96, but once I measured the width, it was too wide and then played with the cast-on stitches until I settled on casting-on 86.
Also, I modified the sleeves by casting-on 43 sts, instead of 53 and lengthen them and glad that I did so, the sleeves fit perfect. Lastly, in the end I settled for the knit side of the garment after taking a long look at the final project and decided that variegated yarn and rev st st do not mix well...lol I have a few wonky stitches, but satisfied with the outcome.
Would you sew it again? Would you recommend it to others: I'm already thinking of doing another one in a solid color and long sleeves. This was a fun knit. Other than changing the yarn and making it a tri-color sweater. The sweater is simple and comfortable.
Like how you take your PR and use it for knitting.
And you didn't venture to far from the pattern. SHOCK!! Glad to hear that it is pretty straight forward as I haven't really looked at the patterns but just keep buying the mag for the pictures/stash! Haha! The fall one is out if you haven't picked it up yet!!
Can't wait to see what you pick for your next knitting project!
It's fantastic! I love the pattern the varigated yarn created. You're a pro!
Very nice. I love it paired with the black belt and pencil skirt. Great job.
Great sweater and fabulous review!
I am so in love with this, it's so pretty! You are so talented!
Wonderful work. I really need to learn to knit.
That looks great! The stripes look great and you'll be able to get a lot of use out of this FO.
It looks wonderful and only 11 days to complete it? Wow!
This sweater is so pretty!!
You whipped that up FAST. Gorgeous work!
I love your knitting review.This looks fantastic! You got it done so quickly.


Atlanta's LightSkinKeisha has just dropped her debut project That's Just The Bottom Line. The project precedes her debut album which is due next year of 2019.
The mixtape features ten tracks with appearances from Blocboy JB, B Smyth and Coca Vango. It also marks a new stride for Keisha, who used her social media stardom to leverage a music career and record deal with L.A. Reid's HitCo.


Home SEO AL DÍA Which external links should you get for your project?
As you all well know, the external links that direct to your website, such as a link from a story in the newspaper, is one of the most important SEO aspects to position your website in search engines.
Google takes into account the backlinks (external links), so that the quality of those links benefit your website, while poor quality external links will harm its positioning.
For this reason, in today's post I will focus on external links that direct to your website that either benefit or harm your project and which are the 'perfect links' that you should get, because they will never be penalized by Google.
It has many outbound links from the Footer or Blogroll.
From a blog with a lot of authority in the domain and that is your same niche in the market. If your website is about clothing, achieve links from textile pages.
You link from within the article, because your content adds something to the article and enriches it.
The content from which you link is widely shared in social networks.